Adjuvant Comparison and Characterization in Influenza , Chlamydia muridarum, and Coxiella burnetii Vaccines

流感、鼠衣原体和伯氏柯克斯体疫苗的佐剂比较和表征

• 批准号: 10889873
• 负责人: PHILIP FELGNER
• 金额: $ 80万
• 依托单位: UNIVERSITY OF CALIFORNIA-IRVINE
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-01 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10889873
• 关键词: Adjuvant; Antigens; Chlamydia muridarum; Communicable Diseases; Coxiella burnetii; Fingerprint; Goals; Immune; Immunologics; Influenza; Side; Tissues; Vaccines; Work; clinically relevant; flu; programs; vaccine development

The goal of the Adjuvant Comparison and Characterization (ACC) program is to support side-by-side comparison of adjuvants in combination with clinically relevant vaccine/antigen platforms, and to establish both systemic and tissue-specific immunological profiles (“immune fingerprints”) of adjuvants that work through different mechanisms in the context of Influenza (flu), Chlamydia muridarum (Cm), and Coxiella burnetii (Cb).

佐剂比较和表征（ACC）项目的目标是支持佐剂与临床相关疫苗/抗原平台的并排比较，并建立佐剂在流感（flu）、muridarum衣原体（Cm）和伯纳氏杆菌（Cb）中通过不同机制起作用的系统和组织特异性免疫图谱（“免疫指纹”）。